Skip to main content
. 2022 Mar 17;13:829366. doi: 10.3389/fimmu.2022.829366

Figure 3.

Figure 3

Survival analysis according to the expression status of CD56 in patients with early stage NKTCL. (A) Overall survival (OS); (B) Progression-free survival (PFS).